1. Home
  2. PLBL vs TMDX Comparison

PLBL vs TMDX Comparison

Compare PLBL & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBL

Polibeli Group Ltd Class A Ordinary Shares

HOLD

Current Price

$5.46

Market Cap

3.0B

Sector

N/A

ML Signal

HOLD

TMDX

TransMedics Group Inc.

HOLD

Current Price

$74.43

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBL
TMDX
Founded
2021
1998
Country
Indonesia
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PLBL
TMDX
Price
$5.46
$74.43
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$148.22
AVG Volume (30 Days)
9.5K
1.4M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
382.18
EPS
N/A
0.20
Revenue
N/A
$605,494,000.00
Revenue This Year
N/A
$24.25
Revenue Next Year
N/A
$18.75
P/E Ratio
N/A
$355.70
Revenue Growth
N/A
37.13
52 Week Low
$5.21
$60.11
52 Week High
$13.48
$156.00

Technical Indicators

Market Signals
Indicator
PLBL
TMDX
Relative Strength Index (RSI) 32.62 48.93
Support Level N/A $64.90
Resistance Level $8.27 $120.60
Average True Range (ATR) 0.66 3.91
MACD -0.12 2.21
Stochastic Oscillator 17.37 92.52

Price Performance

Historical Comparison
PLBL
TMDX

About PLBL Polibeli Group Ltd Class A Ordinary Shares

Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: